SCHEMBL24037525

SCHEMBL24037525

CC(C)(C)c1coc2nccc-2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 3/20 0.41
▸ KIF11 P52732 2/20 0.41
▸ S1PR3 Q99500 2/20 0.41
▸ NPC1 O15118 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ LMNA P02545 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NOTUM Q6P988 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.32
▸ HTR1D P28221 1/20 0.32
▸ ADRA1A P35348 1/20 0.32
▸ NISCH Q9Y2I1 1/20 0.32
▸ HPGDS O60760 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ LTA4H P09960 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12388585 0.77 KIF11 (0.53) S1PR1KIF11S1PR3NPC1RAB9A
SCHEMBL26247541 0.75 GRM5 (0.37) S1PR1NPC1RAB9ATP53NOTUM
SCHEMBL13222357 0.72 LTA4H (0.50) S1PR1KIF11NPC1RAB9ALMNA
SCHEMBL24037309 0.70 NOTUM (0.36) NPC1RAB9ATP53MAPTNOTUM
SCHEMBL24037307 0.70 CCR1 (0.33) KIF11NPC1RAB9AKDM4EL3MBTL1
SCHEMBL14752258 0.70 HPGDS (0.39) S1PR1KIF11S1PR3HPGDSLTA4H
SCHEMBL14310734 0.67 HPGDS (0.43) KIF11NPC1RAB9ALMNANOTUM
SCHEMBL15158461 0.66 LTA4H (0.41) S1PR1HPGDSLTA4H
SCHEMBL17275735 0.65 DYRK1A (0.46) S1PR1S1PR3HPGDSLTA4H
SCHEMBL29723351 0.65 DYRK1A (0.46) S1PR1S1PR3HPGDSLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814379-B2 Cyano quinoline amide compounds as HER2 inhibitors and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-14 — — US disclosed
US-20210355119-A1 CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. 2021-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814379-B2 Cyano quinoline amide compounds as HER2 inhibitors and methods of use ERBB2, EGFR, ERBB3 S1PR1 4576/4885KIF11 3905/4885S1PR3 4308/4885
US-20210355119-A1 CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE ERBB2, EGFR, ERBB3 S1PR1 4585/4885KIF11 3958/4885S1PR3 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback